• 1
    British Columbia Provincial Blood Coordinating Office. IVIG Utilization Management Handbook, 1st edn. BC Provincial Blood Coordinating Office, British Columbia, Canada, 2002.
  • 2
    Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000;34:2959.
  • 3
    Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol 2003;10:1116.
  • 4
    Christiansen OB, Nielsen HS, Pedersen B. Active or passive immunization in unexplained recurrent miscarriage. J Reprod Immunol 2004;62:4152.
  • 5
    Omwandho CO, Gruessner SE, Roberts TK, Tinneberg HR. Intravenous immunoglobulin: modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin Chem Lab Med 2004;42:35970.
  • 6
    British Columbia Provincial Blood Coordinating Office. The supply and cost of IVIG. Blood Matters 2002;4:12.
  • 7
    Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:128691.
  • 8
    Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:17788.
  • 9
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized trials: is blinding necessary? Control Clin Trials 1996;17:112.
  • 10
    Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod 1995;10:26905.
  • 11
    Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:3337.
  • 12
    Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997;12:238892.
  • 13
    Stephenson MDHW. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39:828.
  • 14
    Jablonowska B, Selbing A, Palfi M, Ernerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod 1999;14:83841.
  • 15
    Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002;17:80916.
  • 16
    Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:72831.
  • 17
    Mueller EG. Intravenous immunoglobulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol 1994;101:10727.
  • 18
    Coulam CB, Stern JJ, Bustillo M. Ultrasonographic findings of pregnancy losses after treatment for recurrent pregnancy loss: intravenous immunoglobulin versus placebo. Fertil Steril 1994;61:24851.
  • 19
    Coulam CB. Alternative treatment to lymphocyte immunization for treatment of recurrent spontaneous abortion. Immunotherapy with intravenous immunoglobulin for treatment of recurrent pregnancy loss: American Experience. Am J Reprod Immunol 1994;34:3337.
  • 20
    Daya S, Gunby J, Clark DA. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol 1998;39:6976.
  • 21
    Daya S, Gunby J, Porter F, Scott J, Clark DA. Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. Hum Repord Update 1999;5:47582.
  • 22
    Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:2537.
  • 23
    Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:40813.